Leukotriene B4 (LTB4) is a lipid mediator that activates leukocytes and is involved in host defense and inflammation. BLT1, a high-affinity receptor for LTB4 (originally termed BLT), is expressed exclusively in inflammatory cells and is inducible in macrophages upon activation. The mechanisms of tissue-specific expression and induction of BLT1 are important for the understanding of mechanism of onset and the potential treatment of inflammatory disorders. Here, we report the genomic structure and a promoter analysis of the human BLT1 gene, with an emphasis on the mechanism of cell-specific transcription. No TATA or CAAT elements exist around the transcription initiation sites, but a GC-rich sequence is observed in this region. A reporter gene assay revealed that a region ∼80 basepair upstream from the initiator sequence is required for the basal transcription of the BLT1 gene. Sp1 was found to be a major activator of basal transcription by electrophoretic mobility shift assays and site-directed mutagenesis. The CpG sites of the BLT1 promoter region were highly methylated in BLT1-nonexpressing cells, but not methylated in BLT1-expressing cells. Further, methylation of this region in vitro inhibited the promoter activity to ∼15% of the control. Thus, methylation at CpG sites in the promoter region is important for cell-specific transcription of the BLT1 gene. The promoter region of the BLT1 gene is localized within the open reading frame (ORF) of the BLT2 gene, which encodes a low-affinity receptor for LTB4 (Yokomizo, T., K. Kato, K. Terawaki, T. Izumi, and T. Shimizu. 2000. J. Exp. Med. 192:421–431). To our knowledge, this is the first example of “promoter in ORF” in higher eukaryotes.
Skip Nav Destination
Article navigation
7 August 2000
Article|
August 08 2000
Cell-Specific Transcriptional Regulation of Human Leukotriene B4 Receptor Gene
Kazuhiko Kato,
Kazuhiko Kato
aDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
cPharmaceutical Research Center, Meiji Seika Kaisha, Limited, Yokohama 222-8567, Japan
Search for other works by this author on:
Takehiko Yokomizo,
Takehiko Yokomizo
aDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
bCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation, Tokyo 113-0033, Japan
Search for other works by this author on:
Takashi Izumi,
Takashi Izumi
aDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
bCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation, Tokyo 113-0033, Japan
Search for other works by this author on:
Takao Shimizu
Takao Shimizu
aDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
bCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation, Tokyo 113-0033, Japan
Search for other works by this author on:
Kazuhiko Kato
aDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
cPharmaceutical Research Center, Meiji Seika Kaisha, Limited, Yokohama 222-8567, Japan
Takehiko Yokomizo
aDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
bCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation, Tokyo 113-0033, Japan
Takashi Izumi
aDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
bCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation, Tokyo 113-0033, Japan
Takao Shimizu
aDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
bCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation, Tokyo 113-0033, Japan
Abbreviations used in this paper: EMSA, electrophoretic mobility shift assay; GPCR, G protein–coupled receptor; LTB4, leukotriene B4; ORF, open reading frame; RACE, rapid amplification of cDNA ends; UTR, untranslated region.
Received:
March 27 2000
Accepted:
April 18 2000
Revision Requested:
May 03 2000
Online ISSN: 1540-9538
Print ISSN: 0022-1007
© 2000 The Rockefeller University Press
2000
The Rockefeller University Press
J Exp Med (2000) 192 (3): 413–420.
Article history
Received:
March 27 2000
Accepted:
April 18 2000
Revision Requested:
May 03 2000
Citation
Kazuhiko Kato, Takehiko Yokomizo, Takashi Izumi, Takao Shimizu; Cell-Specific Transcriptional Regulation of Human Leukotriene B4 Receptor Gene. J Exp Med 7 August 2000; 192 (3): 413–420. doi: https://doi.org/10.1084/jem.192.3.413
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement